SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans
about
Optimal management of genital herpes: current perspectivesNanoparticles as potential new generation broad spectrum antimicrobial agentsExploiting dendrimer multivalency to combat emerging and re-emerging infectious diseasesHerpes Genitalis: Diagnosis, Treatment and PreventionClinical Translation of Nanomedicine.Nanotechnology in the war against cancer: new arms against an old enemy - a clinical view.Controlling the HIV/AIDS epidemic: current status and global challengesA review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya.Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities.Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides.Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage.Soluble Immune Mediators and Vaginal Bacteria Impact Innate Genital Mucosal Antimicrobial Activity in Young Women.Polymeric drugs: Advances in the development of pharmacologically active polymers.Polyethylene glycol-functionalized poly (Lactic Acid-co-Glycolic Acid) and graphene oxide nanoparticles induce pro-inflammatory and apoptotic responses in Candida albicans-infected vaginal epithelial cellsDevelopment and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.Efficacy of HIV antiviral polyanionic carbosilane dendrimer G2-S16 in the presence of semenA modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo.Vaginal concentrations of lactic acid potently inactivate HIVDendrimers as potential therapeutic tools in HIV inhibition.Dendrimers for gene delivery--a potential approach for ocular therapy?Vaginal drug delivery: strategies and concerns in polymeric nanoparticle development.Nanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity.Polymeric anti-HIV therapeutics.Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease.Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.Beyond HIV microbicides: multipurpose prevention technology products.New Modalities for Challenging Targets in Drug Discovery.Smart nanoparticles as targeting platforms for HIV infections.Polypeptide-Based Conjugates as Therapeutics: Opportunities and Challenges.On-demand microbicide products: design matters.Polymeric therapeutic delivery systems for the treatment of infectious diseases.Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition.Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.Hydrophobic-core PEGylated graft copolymer-stabilized nanoparticles composed of insoluble non-nucleoside reverse transcriptase inhibitors exhibit strong anti-HIV activity.Simulations reveal that the HIV-1 gp120-CD4 complex dissociates via complex pathways and is a potential target of the polyamidoamine (PAMAM) dendrimer.Progress in Nanomedicine: Approved and Investigational Nanodrugs.Optimising the collection of female genital tract fluid for cytokine analysis in pregnant women.
P2860
Q26746041-992515AE-D141-4C2E-9653-938AC7D17F26Q26795444-14B688FC-E8DF-460A-BB95-9C83FD5103FCQ26852693-09F02A93-9496-4AE5-BC3B-243207C37B9BQ28067618-84A856E7-35C7-4797-86A7-CE21AA21697CQ30355939-FE52A8D3-2656-4296-8FE9-0FFB3C7F6ED9Q30376531-39F00334-A9D5-4666-A993-091DB997AC25Q30420558-A2EA9FB4-FA4A-441C-BDB9-79CF17EF253CQ30431343-FBD97D30-5D88-4071-9E41-105E7AD46B7CQ33821090-C7688632-F67C-4C82-A3F4-56D1B2EF6005Q34434160-8FD9D29B-01C2-493A-AFC6-D5079674F375Q34566597-571DC672-E19E-4614-B4ED-4B20A7F55541Q35213456-FDE19899-A453-4DDC-9F57-B0C06DE9F478Q35683986-42481D87-7DB2-430E-ACD0-043BD60FE483Q36068677-5896A484-1FC4-4D11-9DAB-9C737FA356BDQ36307604-C3D63F21-1E88-4854-986E-5E9A0401A1D3Q36332073-61F8E43D-44DB-42A0-9428-0B92D598F5E6Q36442232-D91117BC-1212-4E05-9645-234407C5AF16Q36967950-1643B32A-574C-435A-B46E-90D3F723F2BAQ37036620-43D14608-DD7C-4ED5-AC81-D76028DC5AD4Q37095477-9A9004B2-2601-498A-BC04-A94229A2EF5EQ38123954-B55F2F20-A63F-4105-A345-F08D0D7812E4Q38196447-7C948C48-1CE6-46C4-9A5C-603788B9ACDCQ38222809-E8821906-4F62-4976-A3BB-1C86BD0AC349Q38233071-5A8FB67F-7277-4DF5-A836-A15A899EFD73Q38245819-60DEDC90-FF91-49AC-B210-94F4CE268566Q38248209-D969C3A3-02C1-4B37-8942-D548F5A19633Q38260862-E1BBDDA0-A518-4393-819A-DA5145DB58FCQ38261814-FD0B5C3D-2BD4-44CF-A567-5094AA124944Q38289100-FB1B0BB6-EB87-4CFA-8C4C-98BC856840ECQ38887077-4CE490F6-1C88-420B-8515-560242231510Q38983708-F24DBB10-5941-40C3-9342-69D0181ED6FFQ39356290-E73E169F-E059-4460-8FA6-91019E96AA71Q39386505-57863C74-3CD8-4C2A-A3F9-4EADA45D8874Q40254597-F89AE094-0AE2-4110-B1DE-5F6475180E30Q41033215-6A0C051C-806A-482C-8CC0-67BF0012DEC2Q41339468-90DC80E2-9C54-424E-B7AC-0808AA94735EQ42050799-938426A7-6EB8-43AB-A161-7FC670384F90Q42283259-212619D7-BE1B-4644-B92D-A5165CEBBEEEQ49188363-6CD60CB8-5AB3-4D11-8492-C3AB2D68AA09Q55362691-994981C5-A2D7-44EA-AC78-EBE3C2C9AE21
P2860
SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
SPL7013 Gel (VivaGel®) retains ...... ginal administration in humans
@ast
SPL7013 Gel (VivaGel®) retains ...... ginal administration in humans
@en
SPL7013 Gel (VivaGel®) retains ...... ginal administration in humans
@nl
type
label
SPL7013 Gel (VivaGel®) retains ...... ginal administration in humans
@ast
SPL7013 Gel (VivaGel®) retains ...... ginal administration in humans
@en
SPL7013 Gel (VivaGel®) retains ...... ginal administration in humans
@nl
prefLabel
SPL7013 Gel (VivaGel®) retains ...... ginal administration in humans
@ast
SPL7013 Gel (VivaGel®) retains ...... ginal administration in humans
@en
SPL7013 Gel (VivaGel®) retains ...... ginal administration in humans
@nl
P2093
P2860
P3181
P1433
P1476
SPL7013 Gel (VivaGel®) retains ...... ginal administration in humans
@en
P2093
Andrew Humberstone
Ashley Davie
Clare F Price
David Tyssen
Gareth R Lewis
Peter Hodsman
Secondo Sonza
Shirley Xia
Sonya Evans
Thomas R Moench
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0024095
P407
P577
2011-09-15T00:00:00Z